Christofer Siegfried Tautermann

This inventor holds 8 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: Centrexion Therapeutics Corporation, Boehringer Ingelheim International Gmbh. Active years: 2014-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christofer Siegfried Tautermann. Retrieved from https://idiyas.com/inventor/christofer-siegfried-tautermann

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 3)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 8.5

ph-index = 3

Forward Citations = 28(Granted Patents)

Location History:

Biberach, DE (2014 - 2023)
Biberach an der Riss, DE (2023 - 2024)

Company Filing History:

5 out of 36

Centrexion Therapeutics Corporation

patents

3 out of 1,562

Boehringer Ingelheim International Gmbh

patents

Years Active: 2014-2025

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12209094 - CCR2 receptor antagonists and uses thereof (2025-01-28),

2. 11992494 - Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists (2024-05-28),

3. 11766443 - Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists (2023-09-26),

4. 11731981 - CCR2 receptor antagonists and uses thereof (2023-08-22),

5. 11046706 - CCR2 receptor antagonists and uses thereof (2021-06-29),

6. 10196402 - CCR2 receptor antagonists and uses thereof (2019-02-05),

7. 9670222 - CCR2 receptor antagonists and uses thereof (2017-06-06),

8. 8765949 - CCR2 receptor antagonists and uses thereof (2014-07-01),

Title: The Innovations of Christofer Siegfried Tautermann

Introduction:

Christofer Siegfried Tautermann, a prolific inventor based in Biberach an der Riss, Germany, has made significant contributions to the field of pharmaceuticals with a total of 6 patents under his name.

Latest Patents:

Among his latest patents is the groundbreaking invention of Cyclopentathiophene carboxamide derivatives as platelet-activating factor receptor antagonists. These compounds have shown promise in treating diseases influenced by antagonizing the activity mediated by the platelet-activating factor receptor. Additionally, Tautermann's work on CCR2 receptor antagonists showcases novel approaches in treating pulmonary diseases such as asthma and COPD.

Career Highlights:

Tautermann has lent his expertise to esteemed companies such as Centrexion Therapeutics Corporation and Boehringer Ingelheim International GmbH, where he has demonstrated his proficiency in drug discovery and development.

Collaborations:

Throughout his career, Tautermann has collaborated with talented individuals in the field, including notable coworkers like Heiner Ebel and Sara Frattini, contributing to a diverse and innovative work environment.

Conclusion:

In conclusion, Christofer Siegfried Tautermann's dedication to innovation in pharmaceuticals has resulted in impactful patents that have the potential to significantly improve the treatment of various diseases. His collaborations and career highlights underscore his commitment to advancing the field of medicine through inventive solutions.

Profile summary based on public USPTO records.